tiprankstipranks
Trending News
More News >
CVS Health Corp (CVS)
NYSE:CVS

CVS Health (CVS) AI Stock Analysis

Compare
13,687 Followers

Top Page

CV

CVS Health

(NYSE:CVS)

Rating:69Neutral
Price Target:
$68.00
▲(6.95%Upside)
CVS Health shows strong financial performance and positive earnings call sentiment, contributing significantly to the score. The technical analysis indicates bearish momentum, and while the valuation is reasonable, it reflects a balanced risk-reward profile. The company's strategic innovations and partnerships are promising, though challenges in specific segments pose risks.
Positive Factors
Acquisitions
CVS file buys of Rite Aid stores are seen as a positive and prudent use of capital, providing high return on investment given the solid margin contribution.
Financial Performance
CVS is well-positioned to continue on its path to a recovery in earnings and valuation, which is considered highly attractive.
Strategic Initiatives
New CEO David Joyner made strategic moves that help streamline the business and refocus on important growth drivers.
Negative Factors
Earnings Uncertainty
Uncertainty around earnings quality is likely a reason for CVS's modest underperformance.
Regulatory Challenges
CVS was down in the after-market due to news of additional CMS audits of Medicare Advantage plans.
Regulatory Risks
Headline risk could arise around PBM reform/legislation seeking to break up PBM ownership of pharmacies.

CVS Health (CVS) vs. SPDR S&P 500 ETF (SPY)

CVS Health Business Overview & Revenue Model

Company DescriptionCVS Health Corporation is a leading American healthcare company that operates across multiple sectors, including retail, pharmacy, and health services. The company is headquartered in Woonsocket, Rhode Island, and is one of the largest pharmacy chains in the United States. CVS Health provides a wide array of services and products such as prescription medications, over-the-counter drugs, health and wellness products, and a range of healthcare services through its retail locations, online platforms, and its subsidiary Aetna, a health insurance provider.
How the Company Makes MoneyCVS Health generates revenue through several key streams. The primary source of income is its retail and pharmacy operations, where it sells prescription medications as well as a wide range of health and beauty products, general merchandise, and convenience items. Another significant revenue stream comes from its pharmacy benefit management (PBM) services, which include managing drug benefit programs for insurance companies and other clients. Additionally, CVS Health benefits from its health insurance segment, Aetna, which provides health insurance plans and services to individuals and businesses. The company's MinuteClinic locations offer various health services, further diversifying its revenue. Strategic partnerships with healthcare providers and insurers, as well as initiatives in digital health and telemedicine, also contribute to its earnings.

CVS Health Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down sales across different business units, revealing which areas contribute most to growth and where the company might face challenges or opportunities.
Chart InsightsCVS Health's revenue growth across all segments is robust, with the Health Care Benefits and Health Services segments showing significant year-over-year increases, reflecting strong market demand and strategic execution. The Pharmacy and Consumer segment also saw double-digit growth, driven by increased prescription volumes. However, challenges like exiting the individual exchange business and legislative impacts in Arkansas could pose risks. Despite these hurdles, CVS's increased EPS guidance and strategic partnerships, such as expanding GLP-1 access, underscore its commitment to innovation and market leadership.
Data provided by:Main Street Data

CVS Health Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: -4.69%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Neutral
CVS Health delivered strong financial results in Q1 2025 and increased its full-year EPS guidance, reflecting solid performance across all segments. The company is leading in market innovation with expanded access to GLP-1 medications and growth in pharmacy market share. However, challenges persist in individual exchange products, legislative impacts in Arkansas, and elevated medical cost trends. The overall sentiment is cautiously optimistic with strong highlights, but significant lowlights remain.
Q1-2025 Updates
Positive Updates
Strong Financial Performance in Q1 2025
CVS Health reported first quarter adjusted earnings per share of $2.25 and adjusted operating income of $4.6 billion. Revenue for the quarter was nearly $95 billion, marking a 7% increase over the prior year.
Increased Full Year 2025 EPS Guidance
The company raised its full year 2025 adjusted EPS guidance to a range of $6 to $6.20, up from the previous range of $5.75 to $6, reflecting solid performance and execution across all business segments.
Expansion in GLP-1 Access
CVS announced a partnership with Novo Nordisk to increase access to Wegovy for members at a more affordable price, demonstrating the value of its integrated model and continuing leadership in market innovation.
Pharmacy Market Share Growth
Retail pharmacy script share in Q1 grew to approximately 27.6%, an increase of approximately 70 basis points from the same period last year, driven by strong execution and superior customer experiences.
Successful Leadership Transition
The appointments of Brian Newman as Chief Financial Officer and Amy Compton-Phillips as Chief Medical Officer are expected to support continued momentum and strategic execution.
Negative Updates
Challenges in Individual Exchange Products
CVS experienced continued underperformance from individual exchange products and plans to exit the states where Aetna independently operates ACA plans effective 2026, citing no near or long-term pathway for improvement.
Impact of Arkansas Legislation
Legislation in Arkansas could disrupt access to CVS pharmacies for thousands of patients, potentially increasing costs for employers and consumers, and affecting more than 10,000 people with complex conditions.
Elevated Medical Cost Trends
Medical cost trends remained high, especially in Medicare, including in-patient, outpatient, and medical pharmacy categories, although there are early signs of stabilization.
Potential Vaccine Demand Impact
CVS is monitoring potential changes in consumer sentiment towards vaccines that may impact market demand, particularly concerning COVID-19 vaccines.
Company Guidance
During the CVS Health Q1 2025 earnings call, the company reported a strong financial performance, with first quarter adjusted earnings per share (EPS) of $2.25 and adjusted operating income of $4.6 billion. CVS Health increased its full-year 2025 adjusted EPS guidance to a range of $6 to $6.20, up from the previous range of $5.75 to $6. The company generated nearly $95 billion in revenue, a 7% increase year-over-year, driven by growth across all segments. The healthcare benefits segment generated nearly $35 billion in revenue, an 8% increase, while the health services segment saw revenues of over $43 billion, reflecting an 8% growth. The pharmacy and consumer wellness segment recorded nearly $32 billion in revenues, an 11% increase compared to the prior year. CVS also processed and dispensed over 1.7 billion prescriptions annually, with a 7% increase in same-store prescription volumes. However, the company is exiting the individual exchange business in 2026, projecting variable losses of $350 million to $400 million for 2025. CVS Health remains committed to innovation and improving healthcare access and affordability through strategic partnerships and digital solutions.

CVS Health Financial Statement Overview

Summary
CVS Health demonstrates strong revenue growth and stable profitability, though challenged by rising operational costs and leverage. The company's solid equity position and cash flow generation support future growth prospects.
Income Statement
78
Positive
CVS Health demonstrates strong revenue growth with a 17.5% increase from 2022 to 2025 TTM. The company's gross profit margin and net profit margin are stable, reflecting robust operational efficiency. However, the decline in EBIT margin from 2023 to 2025 TTM indicates rising operational costs. Despite this, EBITDA margin remains favorable, showcasing consistent earnings before major deductions.
Balance Sheet
70
Positive
The balance sheet reflects a solid equity base with an equity ratio of approximately 30% in 2025 TTM, suggesting financial stability. However, the debt-to-equity ratio is relatively high at 1.06, indicating leverage risks. ROE is healthy, demonstrating efficient use of shareholder funds to generate net income.
Cash Flow
65
Positive
CVS Health shows stable cash flow generation, with positive free cash flow and a high operating cash flow to net income ratio. However, free cash flow has decreased from 2022 to 2025 TTM, reflecting increased capital expenditures and potential challenges in maintaining cash flow growth.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
378.96B372.81B357.78B322.47B292.11B268.71B
Gross Profit
53.24B51.40B54.43B54.50B52.12B49.05B
EBIT
9.62B8.52B13.74B7.95B13.31B13.91B
EBITDA
14.82B13.68B18.20B12.35B17.53B17.12B
Net Income Common Stockholders
5.28B4.61B8.34B4.31B8.00B7.18B
Balance SheetCash, Cash Equivalents and Short-Term Investments
12.65B10.99B11.46B15.72B12.53B10.85B
Total Assets
255.59B253.22B249.73B228.28B233.00B230.72B
Total Debt
81.21B82.92B79.39B70.73B76.00B85.04B
Net Debt
71.14B74.33B71.19B57.79B66.59B77.19B
Total Liabilities
178.47B177.49B173.09B156.51B157.62B161.01B
Stockholders Equity
76.93B75.56B76.46B71.47B75.08B69.39B
Cash FlowFree Cash Flow
5.94B6.33B10.39B13.45B15.74B13.43B
Operating Cash Flow
8.76B9.11B13.43B16.18B18.27B15.87B
Investing Cash Flow
-6.28B-7.61B-20.89B-5.05B-5.26B-5.53B
Financing Cash Flow
-2.24B-1.14B2.68B-10.52B-11.36B-7.70B

CVS Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price63.58
Price Trends
50DMA
65.08
Negative
100DMA
62.80
Positive
200DMA
58.65
Positive
Market Momentum
MACD
-0.44
Negative
RSI
49.83
Neutral
STOCH
75.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVS, the sentiment is Positive. The current price of 63.58 is above the 20-day moving average (MA) of 62.65, below the 50-day MA of 65.08, and above the 200-day MA of 58.65, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 75.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVS.

CVS Health Risk Analysis

CVS Health disclosed 47 risk factors in its most recent earnings report. CVS Health reported the most risks in the “Ability to Sell” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our Health Care Delivery Businesses Face Unique Risks. Q4, 2024

CVS Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
CNCNC
77
Outperform
$27.45B8.2112.59%8.85%33.30%
HUHUM
72
Outperform
$27.84B16.3110.09%1.53%10.09%-12.18%
ELELV
71
Outperform
$88.87B15.3514.24%1.68%6.63%-3.26%
CICI
71
Outperform
$83.40B17.3012.37%1.83%24.65%48.38%
UNUNH
69
Neutral
$275.06B12.6824.33%2.77%8.68%45.24%
CVCVS
69
Neutral
$80.43B15.197.00%4.18%4.84%-26.54%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CVS
CVS Health
63.58
5.96
10.34%
CNC
Centene
55.16
-14.68
-21.02%
CI
Cigna
312.18
-20.52
-6.17%
HUM
Humana
230.70
-114.48
-33.17%
UNH
UnitedHealth
303.22
-183.99
-37.76%
ELV
Elevance Health
393.36
-136.88
-25.81%

CVS Health Corporate Events

Executive/Board ChangesShareholder Meetings
CVS Health Elects Board at Annual Meeting
Neutral
May 20, 2025

At the CVS Health Corporation Annual Meeting of Stockholders held on May 15, 2025, all 13 nominees for the Board of Directors were elected for a one-year term. The stockholders approved the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2025 and the advisory approval of executive compensation. However, a stockholder proposal to reduce the threshold for stockholder rights to act by written consent was not approved.

The most recent analyst rating on (CVS) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on CVS Health stock, see the CVS Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
CVS Health Announces Key Leadership Changes
Positive
Apr 8, 2025

On April 7, 2025, CVS Health announced key leadership changes effective in May 2025. Brian O. Newman was appointed as the Executive Vice President and Chief Financial Officer, succeeding Thomas F. Cowhey, who will transition to a strategic advisor role. Additionally, Amy L. Compton-Phillips was named Executive Vice President and Chief Medical Officer. These appointments are part of CVS Health’s strategy to enhance its leadership team and continue its growth in delivering health care services to millions of Americans.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.